VYNE Therapeutics Inc. (VYNE) News
Filter VYNE News Items
VYNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VYNE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental VitiligoOnce-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025“Repibresib” approved as the non-proprietary name for VYN201 by USAN BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions w |
US Penny Stocks To Watch In December 2024As the U.S. equities market stumbles toward the end of 2024, with the Dow and S&P 500 on track to post monthly losses, investors are increasingly looking for opportunities beyond large-cap stocks. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or less-established companies that can offer significant value potential. By focusing on those with robust financials and growth potential, investors might uncover promising opportunities in these overlooked segments... |
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD dataH.C. Wainwright notes VYNE Therapeutics (VYNE) disclosed positive topline data from the MAD portion of its Phase 1a SAD/MAD trial assessing VYN202 in healthy volunteers. VYN202 is the company’s orally administrated BETi with strong specificity for the BD2 domain of BRD4. After reviewing the data, the firm maintains VYN202 represents significant clinical and value generating potential for the company and the stock. Wainwright thinks the data, in tandem with encouraging Phase 1 SAD data, robustly |
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET InhibitorPromising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitorsVYN202 demonstrated robust pharmacodynamic activity including evidence of target engagement and significant inhibition of inflammatory biomarkers relevant |
VYNE Therapeutics initiated with a Buy at BTIG on I&I potentialBTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in large inflammation and immunology, or I&I, opportunities, notes the analyst, who adds that the class has well-understood relevance in oncology, but its potential in I&I is “a more recent revelation largely owed to efforts” by VYNE. The company’s lead program, VYN201, is a topical BET inhibitor that the firm sees having high odds of emerging as the next |
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsVYNE Therapeutics ( NASDAQ:VYNE ) Third Quarter 2024 Results Key Financial Results Net loss: US$12.2m (loss widened by... |
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateVYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRIDGEWATER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediat |
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET InhibitorVYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing |
VYNE Therapeutics to Participate in September Investor ConferencesBRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024, New York, NYFormat: One-on-one investor |